The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Monthly Archives: August 2011

Monday Biotech Deal Review: August 29, 2011

Welcome to your Monday Biotech Deal Review for August 29, 2011.  In addition to the usual private placement announcements and various commercial transactions, the ongoing hostile bid for Afexa Life Sciences was in the news, with the board of Afexa confirming its recommendation to shareholders to not tender their shares pursuant to the unsolicited bid [...]

Q2 2011 in Canadian Healthcare – Commercial Events were the Focus

There is a tendency to focus on clinical and regulatory events when looking at the biotech sector. However, the list of sector events in Equicom’s Q2_2011 Canadian_Healthcare_Review (which I co-author with Ross Marshall, Senior VP at Equicom) shows a greater number of commercial events, including mergers, acquisitions, in-licensing, partnering, R&D agreements and product launches. In the initial [...]

Valuation and Other Biotech Mysteries – Part 11: Changes in Pharmaceutical Industry Product Portfolios and Strategies

[Ed. This is the eleventh part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] As described in the prior post, the modern pharmaceutical industry has evolved from the patent medicine companies selling [...]

Monday Biotech Deal Review: August 22, 2011

Welcome to your Monday Biotech Deal Review for August 22, 2011.  This week’s deal review is brought to you by Norton Rose OR LLP articling student Keldeagh Lindsay, who will be with us during his articles and assisting in the deal review.  Steven Zuccarelli has done a great job over the summer, and we wish him [...]

Valuation and Other Biotech Mysteries – Part 10: Some Pharmaceutical Industry History

[Ed. This is the tenth part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] Very few novel drug development companies have made, or are likely to make, the transition to profitable and [...]

Friday Science Review: August 19, 2011

Host-Cell Nucleolin, A Helping Hand for RSV University of British Columbia ♦ University of Toronto ♦ Published in Nature Medicine, August 14th, 2011 Human respiratory syncytial virus (RSV), a Pneumovirus that is widely responsible for respiratory tract infections worldwide, appears to use host-cell nucleolin for viral entry. After making the discovery, researchers corroborated their finding [...]

Friday Science Review: August 12, 2011

Acquisition of Animal Gene by Horizontal Transfer University of Ottawa ♦ University of British Columbia ♦ University of Illinois ♦ Albert Einstein College of Medicine Published in Current Biology (Cell Press), August 9, 2011 Researchers have recently made a rather surprising discovery — an animal gene that appears to have been taken up by the microsporidian [...]

Monday Biotech Deal Review: August 8, 2011

Welcome to your Monday Biotech Deal Review for August 8, 2011.  The previous two weeks witnessed a flurry of investment activity, including the filing of final prospectuses by each of Lorus Therapeutics and Atrium Innovations in respect of equity and debt offerings, respectively.  Read on to learn more. 

Friday Science Review: August 5, 2011

High-Throughput Platform for Single-Cell qPCR University of British Columbia ♦ BC Cancer Agency ♦ Centre for Translational and Applied Genomics Published in PNAS, August 1st, 2011 An achievement in microfluidics this week as researchers from the University of British Columbia report on the development of an integrated microfluidics device that performs high-throughput mRNA analysis on [...]

Valuation and Other Biotech Mysteries – Part 9: Retail Investors

[Ed. This is the ninth part in Wayne's series. You can access the whole thing by clicking here. Please leave comments or questions on the blog and Wayne will address them in future posts in this series.] In addition to the private institutional VCs, there are the retail investors who are willing to take similar [...]

Follow

Get every new post delivered to your Inbox.

Join 76 other followers